GB0822836D0 - Method - Google Patents

Method

Info

Publication number
GB0822836D0
GB0822836D0 GBGB0822836.3A GB0822836A GB0822836D0 GB 0822836 D0 GB0822836 D0 GB 0822836D0 GB 0822836 A GB0822836 A GB 0822836A GB 0822836 D0 GB0822836 D0 GB 0822836D0
Authority
GB
United Kingdom
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB0822836.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Priority to GBGB0822836.3A priority Critical patent/GB0822836D0/en
Publication of GB0822836D0 publication Critical patent/GB0822836D0/en
Priority to EP09795519A priority patent/EP2370818A1/en
Priority to JP2011540202A priority patent/JP5671475B2/ja
Priority to CN200980155784.2A priority patent/CN102301236B/zh
Priority to PCT/GB2009/002885 priority patent/WO2010070276A1/en
Priority to US13/139,682 priority patent/US20120027749A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
GBGB0822836.3A 2008-12-15 2008-12-15 Method Pending GB0822836D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB0822836.3A GB0822836D0 (en) 2008-12-15 2008-12-15 Method
EP09795519A EP2370818A1 (en) 2008-12-15 2009-12-15 Method
JP2011540202A JP5671475B2 (ja) 2008-12-15 2009-12-15 方法
CN200980155784.2A CN102301236B (zh) 2008-12-15 2009-12-15 方法
PCT/GB2009/002885 WO2010070276A1 (en) 2008-12-15 2009-12-15 Method
US13/139,682 US20120027749A1 (en) 2008-12-15 2009-12-15 Method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0822836.3A GB0822836D0 (en) 2008-12-15 2008-12-15 Method

Publications (1)

Publication Number Publication Date
GB0822836D0 true GB0822836D0 (en) 2009-01-21

Family

ID=40326133

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0822836.3A Pending GB0822836D0 (en) 2008-12-15 2008-12-15 Method

Country Status (6)

Country Link
US (1) US20120027749A1 (enExample)
EP (1) EP2370818A1 (enExample)
JP (1) JP5671475B2 (enExample)
CN (1) CN102301236B (enExample)
GB (1) GB0822836D0 (enExample)
WO (1) WO2010070276A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888035B2 (en) 2008-10-30 2011-02-15 Caris Mpi, Inc. Methods for assessing RNA patterns
EP3181705A1 (en) 2008-11-12 2017-06-21 Caris Life Sciences Switzerland Holdings GmbH Methods and systems of using exosomes for determining phenotypes
US20130052647A1 (en) * 2010-02-10 2013-02-28 Marianna Goldrick Methods for fractionating and processing microparticles from biological samples and using them for biomarker discovery
CN103237901B (zh) 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 用于治疗诊断的生物标志物
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
KR20140067001A (ko) * 2011-08-08 2014-06-03 카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. 생물지표 조성물 및 방법
EP2758774A4 (en) * 2011-09-22 2015-04-29 Univ Los Andes METHOD FOR MONITORING, DIAGNOSIS AND / OR FORECASTING ACUTE CHILDIER INJURY IN AN EARLY STAGE
JP6254951B2 (ja) * 2012-01-24 2017-12-27 ファイザー・インク 哺乳類の対象における５ｔ４陽性循環腫瘍細胞を検出するための方法および５ｔ４陽性がんの診断の方法
JP5969777B2 (ja) * 2012-03-07 2016-08-17 国立研究開発法人医薬基盤・健康・栄養研究所 肺腺扁平上皮癌の腫瘍マーカー及び診断キット
SG10201404895XA (en) * 2014-08-13 2016-03-30 Agency Science Tech & Res Diagnosis
CN105388055B (zh) * 2015-12-11 2018-03-27 浙江省肿瘤医院 从尿液中分离肿瘤细胞来源的外泌体的方法
CN105505877B (zh) * 2015-12-11 2018-09-28 浙江省肿瘤医院 恶性胸腔积液中分离肿瘤细胞来源的外泌体的方法
WO2018075825A1 (en) * 2016-10-19 2018-04-26 Northwestern University Extracellular vesicle-based diagnostics and engineered exosomes for targeted therapeutics against cancer
JP7007761B2 (ja) * 2017-09-18 2022-03-04 国立台湾大学 甲状腺癌の予後のためのバイオマーカー
WO2021231720A1 (en) * 2020-05-15 2021-11-18 Alexion Pharmaceuticals, Inc. Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0403559A1 (en) * 1988-03-04 1990-12-27 Cancer Research Campaign Technology Limited Improvements relating to antigens
AU2001285157A1 (en) * 2000-08-28 2002-03-13 Oncomedx, Inc. 5t4 rna in plasma and serum as a marker for neoplastic disease
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
DE102004038076A1 (de) * 2004-02-16 2005-09-01 Proteosys Ag Diagnostische Marker für Krebs
WO2005078124A2 (de) * 2004-02-16 2005-08-25 Proteosys Ag Diagnostische marker für krebs
DK1782070T3 (da) * 2004-06-17 2011-01-03 Mannkind Corp Tumorassocieret antigenprofiler i cancerdiagnostik og immunterapi
TW200616662A (en) * 2004-09-10 2006-06-01 Wyeth Corp Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
EP1724585A1 (en) 2005-05-21 2006-11-22 ProteoSys AG Annexin for cancer risk assessment
EP1724586A3 (en) * 2005-05-21 2007-07-04 ProteoSys AG Annexin for cancer risk assessment
EP2604704B1 (en) * 2008-02-01 2018-10-03 The General Hospital Corporation Use of microvesicles in diagnosis and prognosis of brain tumor
EP3181705A1 (en) * 2008-11-12 2017-06-21 Caris Life Sciences Switzerland Holdings GmbH Methods and systems of using exosomes for determining phenotypes
GB201018480D0 (en) * 2010-11-02 2010-12-15 Oxford Biomedica Ltd Factors

Also Published As

Publication number Publication date
CN102301236A (zh) 2011-12-28
WO2010070276A1 (en) 2010-06-24
EP2370818A1 (en) 2011-10-05
JP2012512389A (ja) 2012-05-31
CN102301236B (zh) 2014-06-25
JP5671475B2 (ja) 2015-02-18
US20120027749A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
GB0820927D0 (en) Method
GB0803107D0 (en) Method
GB0818093D0 (en) Method
GB0811360D0 (en) Methods
GB0822836D0 (en) Method
GB0810418D0 (en) Method
GB0804981D0 (en) Method
GB0806569D0 (en) Methods
GB0807409D0 (en) Method
GB0813599D0 (en) Method
GB0815428D0 (en) Method
GB0804690D0 (en) Method
GB0807410D0 (en) Method
EP2309852A4 (en) NOVEL PROCEDURE
GB0809404D0 (en) Method
ZA201101329B (en) Recarburisation method
ZA201008728B (en) Method
GB0813494D0 (en) Method
GB0805862D0 (en) Method
GB0922037D0 (en) Method
GB0812102D0 (en) Method
GB0806186D0 (en) Method
GB0811166D0 (en) Method
GB0810116D0 (en) Method
GB0818142D0 (en) Method